ASKP3 Announces Expert Faculty & Think Tank to Advance Standards of Care & Education for Ketamine Therapy

The American Society of Ketamine Physicians, Psychotherapists & Practitioners (ASKP3), the largest society and think tank for ketamine-based therapy practitioners, has announced the formation of a faculty of experts across multiple disciplines of ketamine therapy. The consortium of experts will serve as a faculty in three pillars – Community, Education, & Standards – with a mission of advancing ketamine-based treatments for mental and physical health.

The interdisciplinary community aims to:

• Establish scientific, ethical and transparent standards among ketamine practitioners.

• Advance the quality of care through the furthering of knowledge, data, the exchange of ideas, and research.

• Foster multidisciplinary collaboration to improve patient outcomes.

• Educate the clinical communities about all aspects of this treatment modality.

• Leverage data to build awareness and understanding among the general population, legislators, regulators and payers.

• Welcome relationships that support the development of other psychedelic therapies.

The interest in psychedelic research and therapy and the proliferation of ketamine clinics across the country, combined with an ongoing mental health crisis, has significantly increased the demand for ketamine-based tools as a treatment for mental health issues and overall well-being. Precise numbers of ketamine practitioners in the country are hard to come by, but ASKP3 currently has more than 400 members with at least 1,000 practitioners having interacted with ASKP3 over the course of 7 years.

Founding Member & President, Sandhya Prashad, MD says: “While the evidence of its efficacy is overwhelming, ketamine as a mental health treatment is still off-label and unregulated. This has created a ‘wild west’ dynamic. As the largest non-profit society of ketamine therapy experts in the country, we feel it is our responsibility to create a collaborative space for dialogue, research, education and the development of ethical and safety standards. It’s more important than ever to come together as one collective voice to protect this valuable and highly-effective treatment.”

Introducing the ASKP3 Faculty:

Julane Andries, LMFT
Michael Banov, MD
Michael Bloch, MD, MS
Carl Bonnett, MD
Glen Brooks, MD
Lori Calabrese, MD
Angelo De Gioannis, MD
John Dougherty, DO, MS
Lara Edinger, DO
David Feifel, MD, PhD
Tiago Gil, MD
Veronika Gold, LMFT
Brandon Kitay, MD, PhD
Sam Ko, MD
Robert Krochmal, MD
Carlene MacMillan, MD
Michael Mantz, MD
Alison McInnes
Rupert McShane, MD, FRCPsych
Brittany O’Brien, PhD
Patrick Oliver, MD
Megan Oxley, MD
Jonathan Reitman, MD
Steve Rosonke, MD
Tatiana Santini, MA, RP, RCC, SEP
Harvey Schwartz, PhD
Scott Shannon, MD
Eric Sienknecht, PsyD
Lowan Stewart, MD
Sunny Strasburg, LMFT
Gita Vaid, MD
Laura Wiginton, LCSW
Jennifer Winegarden, DO
Stefany Wolfsohn, MD
Jeffrey Zabinski, MD, MSW, MA

***

About ASKP3

The American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3) is a non-profit group of professionals dedicated to the safe clinical use of ketamine for mental health disorders and pain conditions. Formed in 2016, ASKP3 represents a growing membership of over 400 multidisciplinary professionals.

Contact Information

Teresa Bigelow

Founder

Spiral5

teresa@spiral5.com